Emageon Inc. Prices Initial Public Offering
2005年2月9日 - 8:18PM
PRニュース・ワイアー (英語)
Emageon Inc. Prices Initial Public Offering BIRMINGHAM, Ala., Feb.
9 /PRNewswire-FirstCall/ -- Emageon Inc. (NASDAQ:EMAG), today
announced the pricing of its initial public offering of 5,000,000
shares of its common stock at a price of $13 a share. All of the
shares are being sold by Emageon. In addition, Emageon has granted
to the underwriters a 30-day over-allotment option to purchase up
to an additional 750,000 shares. Emageon's common stock is expected
to begin trading on The Nasdaq National Market on February 9, 2005
under the symbol "EMAG." Emageon's proceeds from the offering are
expected to be approximately $58.45 million, or $67.52 million if
the underwriters exercise their over- allotment option in full,
after deducting the underwriting discounts and commissions and the
estimated offering expenses. Emageon plans to use the net proceeds
of this offering to repay $4.0 million of its outstanding
subordinated debt and for general corporate purposes, including
working capital, research and development, sales and marketing, and
capital expenditures. Emageon may also use a portion of the net
proceeds for the acquisition of or investment in businesses,
products and technologies that are complementary to its offerings.
Wachovia Capital Markets, LLC and Piper Jaffray & Co. are the
joint book- running managers of the underwriting group. Raymond
James & Associates, Inc. and Friedman, Billings, Ramsey &
Co., Inc. are co-managers. Copies of the final prospectus relating
to the offering may be obtained by contacting Wachovia Capital
Markets, LLC, Syndicate Department, 7 St. Paul Street, Baltimore,
Maryland 21202 or Piper Jaffray & Co., 800 Nicollet Mall, Suite
800, Minneapolis, Minnesota 55402. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. Any offer or
sale will be made only by means of a written prospectus forming
part of the effective registration statement. About Emageon Emageon
provides an enterprise-level information technology solution for
the clinical analysis and management of digital medical images
within health care provider organizations. DATASOURCE: Emageon Inc.
CONTACT: Emageon Investor Relations, +1-205-980-9222, Web site:
http://www.emageon.com/
Copyright